In November 2019, we highlighted the key proposed amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA). The proposed amendments aim to reduce administrative burden for the industry and address misalignments with industry standards and policies in other provinces and territories.
Most of the finalized amendments came into effect on or before January 1, 2020, following public consultations. One notable change from the proposed amendments is the removal of the financial cap on Ordinary Commercial Term (OCT) benefits, as opposed to the previously proposed increase to 25%.
The prohibition against “rebates” under the ODBA and DIDFA does not apply to benefits in accordance with OCT, which are benefits provided in the ordinary course of business that meet certain conditions. Removal of the OCT cap for interchangeable drugs, previously set at 10% of the value of the drug, permits manufacturers to offer greater benefits to wholesalers and pharmacies.
The Government of Ontario has also announced that, as of July 1, 2020*, “Private Label Products” will no longer be prohibited from being designated as a listed drug product or interchangeable.
*On April 7, 2020, the Government of Ontario announced further amendments that changed the effective date retroactively to April 1, 2020 to ensure Ontario’s drug supply amid the COVID-19 outbreak.
Related Publications & Articles
-
New PMPRB Guidelines will not be implemented January 1, 2023
The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the Board on August 18, 2022 w...Read More -
Ontario is the latest jurisdiction to implement a biosimilars transition policy
On December 20, 2022, Ontario announced it is implementing a biosimilars transition policy. Starting March 31, 2023, patients receiving coverage from the Ontario Drug Benefit plan for the following in...Read More -
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the ...Read More